Trovagene TROV Stock News

TrovaGene Inc (NASDAQ: TROV) is yet another stock that’s finding its way up in a dramatic way this morning, and for good reason. The company reported positive data surrounding its lead candidate, Onvansertib. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

TROV Stock Finds It’s Way Up On Onvansertib Data

In an early-morning press release, Trovagene announced positive results from an ongoing Phase 1b/2 clinical trial of onvansertib in combination with FOLFIRI and Avastin. The combination treatment is being assessed as a potential second-line treatment of patients with KRAS-mutated metaststic colorectal cancer, also known as mCRC.

In the release, the company said that Dr. Afsaneh Brazi delivered the data in a virtual oral presentation at the American Association for Cancer Research (AACR) conference on Monday.

Importantly, the first two dose levels, 12mg/m2 and 15mg/m2 have been cleared for safety. The third dose level, 18 mg/m2, is currently enrolling and the maximum tolerated dose has not been reached to date.

Nonetheless, as a result of the cut-off date, the clinical response was observed in seven of eight evaluable patients. That brings the response rate to this combination therapy to about 88%.

TROV also said that it is seeing an important therapeutic response. In the study, decreases in plasma KRAS mutation levels have been demonstrated, which can be used as an early marker for therapeutic response.

In a statement, Dr. Afsaneh Barzi, Principal Investigator in the TROV trial, had the following to offer:

We are encouraged by the level of activity that we are observing with the combination of onvansertib and standard-of-care FOLFIRI and bevacizumab in our patients with KRAS-mutated colorectal cancer. So far we are observing what we had hoped for in this trial – lack of toxicity and positive signs of efficacy. We remain optimistic because we are observing anti-tumor effects of onvansertib, which could present the opportunity for a new treatment designed to attack KRAS-mutant tumors and act synergistically with standard-of-care chemotherapy.

Why This News Is So Important

mCRC is a devastating ailment that represents a very large potential market. Moreover, current treatment options are largely ineffective. In fact, currently available treatments have about a 4% response rate and a median progression free survival rate of about 5.5 months.

While the data from TrovaGene is still very early, seeing an 88% response rate in patients treated with the Onvansertib, FOLFIRI and Avastin combination is exciting news no matter how you slice it.

Should all continue to go well in this and future clinical trials, this combination treatment could be the next blockbuster treatment option in the mCRC space.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts.

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.